rs3804099 — TLR2

Synonymous variant in Toll-Like Receptor 2 affecting mRNA stability and splicing, associated with pulmonary tuberculosis susceptibility, cancer risk modification, and anti-TNF treatment response in inflammatory bowel disease

See your personal result for TLR2

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

TLR2 rs3804099 — A Silent Change With a Functional Shadow

Not all genetic variants that matter change an amino acid. Toll-Like Receptor 2 (TLR2)11 Toll-Like Receptor 2 (TLR2)
the frontline innate immune receptor that detects bacterial lipoproteins, peptidoglycan, and mycobacterial components on the surface of macrophages and dendritic cells carries a synonymous variant — rs3804099, also written as T597C or 19216T/C — where a single nucleotide change in the coding sequence leaves the encoded amino acid identical but may not leave TLR2 function unchanged. In silico analysis predicts a 70% probability that the C allele creates or disrupts a splice site, potentially altering TLR2 mRNA processing and steady-state transcript levels. The variant has been studied across tuberculosis cohorts, cancer registries, inflammatory bowel disease treatment trials, and bacterial infection datasets, painting a picture of a functionally relevant variant whose effect is population-specific and context-dependent.

The rs3804099 C allele is the minor allele in most populations, with frequencies ranging from roughly 12% in Africans to 40% in East Asians, making it far more common globally than the R753Q variant (rs5743708) in the same gene, which is almost exclusively European. This means most users encountering TLR2 findings will have rs3804099 results rather than R753Q results.

The Mechanism

Unlike the R753Q missense variant (rs5743708)22 R753Q missense variant (rs5743708)
which directly disrupts TLR2's TIR domain structure, reducing signaling by 42-fold, rs3804099 does not change the TLR2 protein sequence. Instead, it operates at the RNA level. The nucleotide substitution (c.597T>C in some annotations, placed in exon 3 of TLR2) is predicted to alter splicing regulatory elements33 splicing regulatory elements
exonic splicing enhancers and silencers that guide spliceosome assembly. An in silico analysis found a 70% probability that this substitution affects mRNA splicing, a mechanism increasingly recognized as a route through which synonymous variants influence gene function. A 2022 study in smokers and COPD patients found that individuals with CC homozygosity had significantly less FEV1 decline and that CT heterozygotes showed reduced neutrophil and macrophage numbers over time compared with TT individuals, consistent with altered TLR2 expression or isoform usage. A 2024 study examining TLR-2 expression in response to SARS-CoV-2 spike protein found that C allele carriers (CT and CC genotypes) could not mount the same downregulation of TLR-2 positive non-switched B cells as TT individuals, indicating that the C allele changes how TLR2 responds to viral challenge at the cellular level.

The Evidence

The clearest signal comes from cancer susceptibility, where rs3804099 consistently shows a modest protective effect of the C allele. A meta-analysis of 47 case-control studies comprising 15,851 cancer cases and 21,182 controls44 47 case-control studies comprising 15,851 cancer cases and 21,182 controls
spanning gastric, hepatocellular, colorectal, and other cancers found that carriers of the C allele (CT or CC genotypes) had significantly lower cancer risk compared with TT homozygotes, with overall OR of 0.85 (95% CI 0.74–0.97, p=0.016) in the dominant model. The effect was strongest in Asians (OR 0.69 for CT vs TT, 95% CI 0.55–0.87), consistent with the higher baseline C allele frequency in East Asian populations. For hepatocellular carcinoma specifically, the heterozygous CT genotype was associated with significantly decreased HCC risk compared to TT, in a study of 300 HCC cases and 360 controls. The biological interpretation is that the C allele may increase TLR2-mediated innate immune surveillance of malignant or pre-malignant cells, though the exact mechanism remains under investigation.

For tuberculosis, the picture is more complex. An individual case-control study in 341 Han Chinese TB patients and 386 controls55 341 Han Chinese TB patients and 386 controls
including 230 pulmonary TB and 111 tuberculous meningitis patients found that the CC genotype was associated with increased pulmonary TB susceptibility in a recessive model (OR 2.22, 95% CI 1.18–4.17), with the association specific to pulmonary rather than meningeal TB and more pronounced in males. A Western Chinese cohort found significant associations specifically in retreatment TB (patients who relapsed or failed initial therapy) rather than primary TB. A Han Taiwanese study identified a C-T haplotype across rs3804099 and the adjacent rs3804100 that conferred increased TB risk. However, meta-analyses tell a more cautious story: an earlier Asian-focused meta-analysis of 8 studies (2,175 TB cases, 2,069 controls) found no significant association across genetic models for the T597C variant (OR 0.95, 95% CI 0.86–1.04). A broader meta-analysis found modest significance in the overall pooled population. This discrepancy reflects heterogeneity across populations, TB types, and analytic models — the CC genotype may represent a genuine risk factor in specific ethnic or epidemiological contexts rather than a universal effect.

In inflammatory bowel disease, rs3804099 emerged from a systematic review as a predictor of anti-TNF drug response. A Danish study of 738 IBD patients treated with infliximab or adalimumab66 Danish study of 738 IBD patients treated with infliximab or adalimumab
including 256 UC patients and 482 CD patients found that patients carrying the CT or CC genotype had more than twice the odds of responding to anti-TNF therapy compared with TT homozygotes (OR 2.17, 95% CI 1.35–3.47). The authors proposed that genetically determined reduced IL-1β and IL-6 production (associated with the C allele) may create a lower baseline inflammatory tone that responds more favorably to TNF blockade. This is a pharmacogenomic finding, not a disease susceptibility finding — having the C allele does not predispose to IBD, but if you develop IBD and require biologic therapy, it may predict your response.

Practical Implications

The clinical picture from rs3804099 is genuinely nuanced. The CC genotype occupies an unusual position: it appears to be a risk factor for pulmonary tuberculosis (in certain Asian populations and specifically in retreatment TB contexts), yet simultaneously confers modest protection against several cancers and better response to anti-TNF therapy in IBD. This paradox may reflect the immunological trade-off at the heart of TLR2 biology — a TLR2 that responds more vigorously (TT) is better at initial mycobacterial clearance but may also drive more cancer-promoting chronic inflammation; a TLR2 with altered expression or splicing (CC) may mount a blunted initial anti-mycobacterial response while reducing chronic inflammatory cancer risk.

For the TT genotype, which is the common form, the evidence suggests somewhat more robust initial TLR2-mediated innate immune responses, but without the cancer-protective attenuation of chronic signaling.

Interactions

rs3804099 is studied together with rs380410077 rs3804100
a closely adjacent synonymous TLR2 variant in exon 3 in strong linkage disequilibrium with rs3804099 in Asian populations in haplotype analyses — the C-T haplotype (rs3804099 C + rs3804100 T) appears to be the TB-risk haplotype in Han Taiwanese, suggesting the two variants act together or that rs3804099 tags a broader functional haplotype block.

For individuals who also carry TLR2 R753Q (rs5743708), the innate immune system faces both a structural signaling defect (R753Q) and a potential expression-level alteration (rs3804099) at the same gene, though these two variants are on different haplotype blocks and both appear to reach significance independently in TB studies. Their combined effect has not been formally studied.

Genotype Interpretations

What each possible genotype means for this variant.

TT Common Form Normal

Standard TLR2 variant associated with robust innate immune signaling and typical disease susceptibility

You carry two copies of the common T allele at rs3804099. About 54% of people globally share this genotype, though frequencies vary substantially by ancestry — TT is considerably more common in African populations (~76%) than in East Asian populations (~36%). Your TLR2 gene produces mRNA through the standard splice pattern, and studies suggest TT individuals mount slightly stronger TLR2-mediated innate immune responses. The tradeoff is that the TT genotype confers no cancer-protective attenuation of chronic TLR2 signaling, and some evidence suggests higher susceptibility to Clostridioides difficile infection.

CT C Carrier Intermediate

One C allele — modestly altered TLR2 expression with potential cancer-protective effect and improved anti-TNF response in IBD

You carry one copy of the C allele at rs3804099, found in roughly 38% of people globally. The C allele is predicted to alter TLR2 mRNA splicing, potentially modifying TLR2 expression levels compared with the TT genotype. Studies suggest CT individuals may have a modest cancer risk reduction compared to TT homozygotes (OR ~0.83 in the dominant model across multiple cancer types), and if you develop inflammatory bowel disease requiring anti-TNF biologic therapy, carrying a C allele is associated with approximately twice the odds of clinical response. Tuberculosis data for the heterozygous state is inconsistent across meta-analyses — the CC homozygous genotype carries clearer TB risk signals in specific populations.

CC Homozygous C High Risk

Two C alleles — altered TLR2 mRNA processing with increased pulmonary TB susceptibility in specific populations alongside modest cancer protection

The CC genotype sits at the intersection of multiple immunological trade-offs. In vitro data suggest the C allele alters TLR2 mRNA splicing with ~70% probability according to in silico prediction, and cellular studies in COVID-19 contexts found that CC and CT carriers could not properly downregulate TLR-2+ B cells in response to SARS-CoV-2 spike protein stimulation the way TT individuals could. Whether this reflects reduced TLR2 expression, altered isoform ratios, or modified signaling dynamics is not yet established by direct biochemical studies.

The tuberculosis risk appears population-specific and context-dependent. In the Han Chinese cohort, the risk was confined to pulmonary TB (not tuberculous meningitis) and was more pronounced in males. In retreatment TB — patients who failed first-line therapy or relapsed — the CC genotype was significantly enriched, suggesting it may impair the sustained immune response required to clear persistent mycobacterial infection rather than preventing initial control. Meta-analyses across Asian studies found inconsistent results, with some showing significance and others null results, indicating the CC genotype is a meaningful but context-dependent risk factor rather than a universal determinant.

The cancer protective effect likely reflects the opposite side of the same biology: reduced chronic inflammatory signaling from TLR2 may lower the tumor-promoting inflammation that drives cancer progression, at the cost of slightly attenuated innate immune responses to acute bacterial or mycobacterial challenge.